Keyword Analysis & Research: cx 5461

nature.com

https://www.nature.com/articles/ncomms14432/

Feb 17, 2017 · CX-5461 is an rDNA transcription inhibitor currently in phase I trials for haematologic malignancies. CX-5461 reduces the binding affinity of the SL1 pre-initiation … Author: Hong Xu, Marco Di Antonio, Steven McKinney, Veena Mathew, Brandon Ho, Nigel J O'Neil, Nancy Dos Sant... Is Accessible For Free: True Publish Year: 2017

Author: Hong Xu, Marco Di Antonio, Steven McKinney, Veena Mathew, Brandon Ho, Nigel J O'Neil, Nancy Dos Sant...

Is Accessible For Free: True

Publish Year: 2017

DA: 53 PA: 93 MOZ Rank: 24

medchemexpress.com

https://www.medchemexpress.com/cx-5461.html

CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50 s of 142, 113, and 54 nM in HCT-116, …

DA: 53 PA: 29 MOZ Rank: 13

cellagentech.com

https://www.cellagentech.com/cx-5461/

CX-5461 is a potent, orally bioavailable small molecule inhibitor of rRNA synthesis in cancer cells. It selectively inhibits rRNA synthesis by polymerase I … CAS #: 1138549-36-6 Molecular Weight: 513.61 Chemical Formula: C 27 H 27 N 7 O 2 S Purity: > 98%

CAS #: 1138549-36-6

Molecular Weight: 513.61

Chemical Formula: C 27 H 27 N 7 O 2 S

Purity: > 98%

DA: 100 PA: 29 MOZ Rank: 94

nih.gov

https://pubmed.ncbi.nlm.nih.gov/28211448/

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours G-quadruplex DNAs form four-stranded helical structures and are proposed to play key roles in … Author: Hong Xu, Marco Di Antonio, Steven McKinney, Veena Mathew, Brandon Ho, Nigel J O'Neil, Nancy Dos Sant... Publish Year: 2017

Author: Hong Xu, Marco Di Antonio, Steven McKinney, Veena Mathew, Brandon Ho, Nigel J O'Neil, Nancy Dos Sant...

Publish Year: 2017

DA: 97 PA: 64 MOZ Rank: 68

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533980/

Oct 09, 2021 · CX-5461 is an RNA polymerase I inhibitor that is in clinical trials for both advanced hematological cancers and solid tumors. Experimentally, this drug has been shown to induce a …

DA: 67 PA: 57 MOZ Rank: 38

nih.gov

https://pubmed.ncbi.nlm.nih.gov/24900516/

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics ACS Med Chem Lett . 2012 May 8;3(7):602-6. doi: 10.1021/ml300110s.

DA: 25 PA: 51 MOZ Rank: 10

clinicaltrials.gov

https://clinicaltrials.gov/ct2/show/NCT04890613

May 18, 2021 · CX-5461 (Pidnarulex), a synthetically-derived small molecule that selectively kills HR-deficient cancer cells through the binding and stabilization of G4 DNA structure. Early …

DA: 100 PA: 87 MOZ Rank: 40

targetedonc.com

https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-cx-5461-in-treatment-of-certain-patients-with-breast-or-ovarian-cancer

Jan 26, 2022 · FDA Grants Fast-Track Designation to CX-5461 in Treatment of Certain Patients with Breast or Ovarian Cancer January 26, 2022 Conor Killmurray The FDA has granted a fast …

DA: 57 PA: 7 MOZ Rank: 12

nature.com

https://www.nature.com/articles/s41467-022-31199-2

Jun 24, 2022 · CX-5461 stabilizes G4 in DNA, resulting in replication fork collapse and single-stranded breaks, which convert to double-stranded DNA breaks. CX-5461 was found to be …

DA: 77 PA: 44 MOZ Rank: 18